Preoperative paclitaxel weekly combined with radical gastrectomy for gastric cancer: randomized controlled study

Abstract

Objective To explore the clinical efficacy of preoperative paclitaxel weekly therapy as neoadjuvant chemotherapy combined with radical surgery for gastric cancer. Methods Using a randomized controlled study method, 120 gastric cancer patients admitted to Nanyang Nanshi Hospital from June 2022 to June 2023 were randomly divided into control group and study group, with 60 cases in each group. The patients in control group were treated with gastric cancer radical surgery, while the study group patients received neoadjuvant chemotherapy 2 weeks before surgery, using a paclitaxel weekly therapy mode with a dose of 175 mg/m2 for 2 consecutive weeks, followed by gastric cancer radical surgery. The Barthel index, self-rating anxiety scale (SAS), self-rating depression scale (SDS), visual analog scale (VAS), carcinoembryonic antigen, carbohydrate antigen199 and total adverse reaction rate were compared between two groups. Results After treatment, the Barthel index was higher, while the SAS and SDS scores were lower of patients in the study group than those before treatment and control group (P＜0.05). VAS score, carcinoembryonic antigen, and carbohydrate antigen 199 in the study group were lower than those before treatment and the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the study group and the control group (8.33% vs 6.67%, P>0.05). Conclusion Preoperative paclitaxel weekly therapy as neoadjuvant chemotherapy combined with radical surgery for gastric cancer can improve the anxiety and depression status of patients and increase the overall effective rate.

Keywords

• gastric cancer
• paclitaxel
• neoadjuvant chemotherapy
• radical gastrectomy
• carcinoembryonic antigen
• carbohydrate antigen 199